Surface markers of cancer stem cells in solid tumors

Current Stem Cell Research and Therapy

Volumn 9, Issue 2, 2014, Pages 102-111

  Xia, Pu ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Aldehyde dehydrogenase; Cancer stem cells; Differentiation; Self renew; Surface marker

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ALDEHYDE DEHYDROGENASE; ALPHA6 INTEGRIN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; CD133 ANTIGEN; CD15 ANTIGEN; CD24 ANTIGEN; CD44V ANTIGEN; CD56 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; DECAY ACCELERATING FACTOR; ENDOGLIN; G PROTEIN COUPLED RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; MICROSOMAL AMINOPEPTIDASE; NEUROTROPHIN RECEPTOR P75; PROSTATE STEM CELL ANTIGEN; STAGE SPECIFIC EMBRYO ANTIGEN 4; STEM CELL FACTOR RECEPTOR; THY 1 ANTIGEN; TUMOR MARKER; CELL SURFACE MARKER;

APOPTOSIS; BILE DUCT CARCINOMA; BLADDER CANCER; BREAST CANCER; CANCER INHIBITION; CANCER MORTALITY; CANCER STEM CELL; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; CELL SURFACE; COLORECTAL CANCER; ESOPHAGUS CANCER; FOLLOW UP; GALLBLADDER CARCINOMA; GLIOMA; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; LYMPH NODE METASTASIS; MOUTH SQUAMOUS CELL CARCINOMA; NASOPHARYNX CANCER; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; STOMACH CANCER; TUMOR INVASION; UPREGULATION; UTERINE CERVIX CANCER; CELL ISOLATION; NONHUMAN; SQUAMOUS CELL CARCINOMA;

ANIMALS; ANTIGENS, CD; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 84893021888     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574888X09666131217003709     Document Type: Review

References (162)

1. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66(19): 9339-44.
2. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414(6859): 105-11.
3. Cho RW, Clarke MF. Recent advances in cancer stem cells. Curr Opin Genet Dev 2008; 18(1): 48-53.
4. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3(7): 730-7.
5. Singh JK, Simões BM, Howell SJ, Farnie G, Clarke RB. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res 2013; 15(4): 210.
6. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432(7015): 396-401.
7. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identifi cation and expansion of human colon-cancer-initiating cells. Nature 2007; 445(7123): 111-5.
8. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65(23): 10946-51.
9. Koren A, Motaln H, Cufer T. Lung cancer stem cells: a biological and clinical perspective. Cell Oncol (Dordr) 2013; 36(4): 265-75.
10. Yamashita T, Wang XW. Cancer stem cells in the development of liver cancer. J Clin Invest 2013; 123(5): 1911-8.
11. Chen YC, Chang CJ, Hsu HS, et al. Inhibition of tumorigenicity and enhancement of radiosensitivity in head and neck squamous cell cancer-derived ALDH1-positive cells by knockdown of Bmi-1. Oral Oncol 2010; 46(3): 158-65.
12. Clay MR, Tabor M, Owen J, et al. Single marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck 2010; 32(9): 1195-201.
13. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 2004; 101(3): 781-6.
14. Chiou SH, Yu CC, Huang CY, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res 2008; 14(13): 4085-95.
15. Lim YC, Oh SY, Cha YY, Kim SH, Jin X, Kim H. Cancer stem cell traits in squamospheres derived from primary head and neck squamous cell carcinomas. Oral Oncol 2011; 47(2): 83-91.
16. Sun M, Zhou W, Zhang YY, Wang DL, Wu XL. CD44+gastric cancer cells with stemness properties are chemoradioresistant and highly invasive. Oncol Lett 2013; 5(6): 1793-8.
17. Lan X, Wu YZ, Wang Y, et al. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells. Int J Mol Med2013; 31(2): 315-24.
18. Tirino V, Camerlingo R, Franco R, et al. The role of CD133 in the identification and characterization of tumor-initiating cells in nonsmall-cell lung cancer. Eur J Cardiothorac Surg 2009; 36(3): 446-53.
19. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69-90.
20. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Nat Acad Sci USA 2003; 100(7): 3983-8.
21. Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumorinitiating features. Proc Natl Acad Sci USA 2009; 106(33): 13820-5.
22. Xu JX, Morii E, Liu Y, et al. High tolerance to apoptotic stimuli induced by serum depletion and ceramide in side-population cells: high expression of CD55 as a novel character for side-population. Exp Cell Res 2007; 313(9): 1877-85.
23. Fortunel NO, Otu HH, Ng HH, et al. Comment on "'Stemness': transcriptional profiling of embryonic and adult stem cells" and "a stem cell molecular signature". Science 2003; 302(5644): 393.
24. Meyer MJ, Fleming JM, Lin AF, et al. CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res 2010; 70(11): 4624-33.
25. Springer GF. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med (Brel) 1997; 75(8): 594-602.
26. Cao Y, Karsten U, Otto G, Bannasch P. Expression of MUC1, Thomsen-Friedenreich antigen, Tn, sialosyl-Tn, and alpha2, 6-linked sialic acid in hepatocellular carcinomas and preneoplastic hepatocellular lesions. Virchows Arch 1999; 434(6): 503-9.
27. Lin WM, Karsten U, Goletz S, Cheng RC, Cao Y. Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells. Int J Exp Pathol 2011; 92(2): 97-105.
28. Battula VL, Shi Y, Evans KW, et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest 2012; 122(6): 2066-78.
29. Wright MH, Calcagno AM, Salcido CD, et al. Brca1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 2008; 10(1): R10.
30. Lehmann C, Jobs G, Thomas M, Burtscher H, Kubbies M. Established breast cancer stem cell markers do not correlate with in vivo tumorigenicity of tumor-initiating cells. Int J Oncol 2012; 41(6): 1932-42.
31. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104(24): 10158-63.
32. Kemper K, Grandela C, Medema JP. Molecular identification and targeting of colorectal cancer stem cells. Oncotarget 2010; 1(6): 387-95.
33. Choi D, Lee HW, Hur KY, et al. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J of Gastroenterol 2009; 15(18): 2258-64.
34. + cells in colon cancer cell lines possess stem cell characteristics. Neoplasma 2012; 59(3): 282-8.
35. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445(7123): 106-10.
36. Zou J, Yu XF, Bao ZJ, Dong J. Proteome of human colon cancer stem cells: a comparative analysis. World J of Gastroenterol 2011; 17(10): 1276-85.
37. Barker N, Ridgway RA, van Es JH, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009; 457(7229): 608-11.
38. Walker F, Zhang H-H, Odorizzi A, Burgess AW. LGR5 Is a Negative Regulator of Tumourigenicity, Antagonizes Wnt Signalling and Regulates Cell Adhesion in Colorectal Cancer Cell Lines. PloS One 2011; 6(7): e22733.
39. Takahashi H, Ishii H, Nishida N, et al. Significance of Lgr5(+ve) cancer stem cells in the colon and rectum. Ann Surg Oncol 2011; 18(4): 1166-74.
40. Carney DN, Gazdar AF, Bunn PA, et al. Demonstration of the stem cell nature of clonogenic tumor cells from lung cancer patients. Stem Cells 1982; 1(3): 149-164.
41. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15(3): 504-14.
42. Bertolini G, Roz L, Perego P, et al. Highly tumorigenic lung cancer CD133t cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 2009; 106(38): 16281-6.
43. Chen YC, Hsu HS, Chen YW, et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 2008; 3(7): e2637.
44. Leung EL, Fiscus RR, Tung JW, et al. Non-small cell lung cancer cells expressing cd44 are enriched for stem cell-like properties. PLoS One 2010; 5(11): e14062.
45. Damelin M, Geles KG, Follettie MT, et al. Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells. Cancer Res 2011; 71(12): 4236-46.
46. Qiu X, Wang Z, Li Y, et al. Characterization of sphere-forming cells with stem-like properties from the small cell lung cancer cell line H446. Cancer Lett 2012; 323(2): 161-70.
47. Salcido CD, Larochelle A, Taylor BJ, Dunbar CE, Varticovski L. Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. Br J Cancer 2010; 102(11): 1636-44.
48. Wu C, Wei Q, Utomo V, et al. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res 2007; 67(17): 8216-22.
49. Xia P, Gou WF, Wang JJ, et al. Distinct radiosensitivity of lung carcinoma stem-like side population and main population cells. Cancer Biother Radiopharm. 2013; 28(6): 471-8.
50. Zhang WC, Shyh-Chang N, Yang H, et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 2012; 148(1-2): 259-72.
51. Takaishi S, Okumura T, Tu S, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009; 27(5): 1006-20.
52. Ishimoto T, Oshima H, Oshima M, et al. CD44+ slow cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis. Cancer Sci 2010; 101(3): 673-8.
53. Chen T, Yang K, Yu J, et al. Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients. Cell Res 2012; 22(1): 248-58.
54. Jiang J, Zhang Y, Chuai S, et al. Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype. Oncogene 2012; 31(6): 671-82.
55. Rocco A, Liguori E, Pirozzi G, et al. CD133 and CD44 Cell surface markers do not identify cancer stem cells in primary human gastric tumors. J Cell Physiol 2012; 227(6): 2686-93.
56. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133-metastatic colon cancer cells initiate tumors. J Clin Invest 2008; 118(6): 2111-20.
57. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006; 351(4): 820-4.
58. Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007; 132(7): 2542-56.
59. Yang ZF, Ho DW, Ng MN, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008; 13(2): 153-66.
60. Zhu Z, Hao X, Yan M, et al. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer 2010; 126(9): 2067-78.
61. Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol 2010; 52(2): 280-1.
62. Kimura O, Takahashi T, Ishii N, et al. Characterization of the epithelial cell adhesion molecule (EpCAM)+ cell population in hepatocellular carcinoma cell lines. Cancer Sci 2010; 101(10): 2145-55.
63. Haraguchi N, Ishii H, Mimori K, et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 2010; 120(9): 3326-39.
64. Christ B, P Stock, MM Dollinger. CD13: Waving the flag for a novel cancer stem cell target. Hepatology 2011; 53(4): 1388-90.
65. Rong Y, Wang YX, Sun LX, et al. CD117-positive cells in human hepatocarcinoma cell line HepG2: isolation and evaluation of their stem properties. World Chin J Digestol 2011; 19(36): 3649-55.
66. Becker G, Schmitt-Graeff A, Ertelt V, Blum HE, Allgaier HP. CD117 (c-kit) expression in human hepatocellular carcinoma. Clin Oncol (R Coll Radiol) 2007; 19(3): 204-8.
67. Lee ES, EM Han, YS Kim, et al. Occurrence of c-kit + tumor cells in hepatitis B virus-associated hepatocellular carcinoma. Am J Clin Pathol 2005; 124(4): 31-6.
68. Ye F, Zhou C, Cheng Q, Shen J, Chen H. Stem-cell-abundant proteins Nanog, Nucleostemin and Musashi1 are highly expressed in malignant cervical epithelial cells. BMC Cancer 2008; 8: 108.
69. Gu W, Yeo E, McMillan N, Yu C. Silencing oncogene expression in cervical cancer stem-like cells inhibits their cell growth and selfrenewal ability. Cancer Gene Ther 2011; 18(12): 897-905.
70. Atsumi N, Ishii G, Kojima M, Sanada M, Fujii S, Ochiai A. Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431. Biochem Biophys Res Commun 2008; 373(1): 36-41.
71. López J, Poitevin A, Mendoza-Martínez V, Pérez-Plasencia C, García-Carrancá A Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance. BMC Cancer 2012; 12: 48.
72. Cantz T, Key G, Bleidissel M, et al. Absence of OCT4 expression in somatic tumor cell lines. Stem Cells 2008; 26(3): 692-7.
73. Hang D, Dong HC, Ning T, Dong B, Hou DL, Xu WG. Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma. Dis Esophagus 2012; 25(7): 638-44.
74. Okumura T, Tsunoda S, Mori Y, et al. The biological role of the low-affinity p75 neurotrophin receptor in esophageal squamous cell carcinoma. Clin Cancer Res 2006; 12(17): 5096-103.
75. Huang SD, Yuan Y, Liu XH, et al. Self-renewal and chemotherapy resistance of p75NTR positive cells in esophageal squamous cell carcinomas. BMC Cancer 2009; 9: 9.
76. Zhao JS, Li WJ, Ge D, et al. Tumor initiating cells in esophageal squamous cell carcinomas express high levels of CD44. PLoS One 2011; 6(6): e21419.
77. Smit JK, Faber H, Niemantsverdriet M, et al. Prediction of response to radiotherapy in the treatment of esophageal cancer using stem cell markers. Radiother Oncol 2013; 107(3): 434-41.
78. Tang KH, Dai YD, Tong M, et al. A CD90(+) tumor-initiating cell population with an aggressive signature and metastatic capacity in esophageal cancer. Cancer Res 2013; 73(7): 2322-32.
79. Grotenhuis BA, Dinjens WN, Wijnhoven BP, et al. Barrett's oesophageal adenocarcinoma encompasses tumour-initiating cells that do not express common cancer stem cell markers. J Pathol 2010; 221(4): 379-89.
80. Oates JE, Grey BR, Addla SK, et al. Hoechst 33342 side population identification is a conserved and unified mechanism in urological cancers. Stem Cells Dev 2009; 18(10): 1515-22.
81. She JJ, Zhang PG, Wang ZM, et al. Identification of side population cells from bladder cancer cells by DyeCycle Violet staining. Cancer Biol Ther 2008; 7(10): 1663-8.
82. Falso MJ, Buchholz BA, White RW. Stem-like cells in bladder cancer cell lines with differential sensitivity to cisplatin. Anticancer Res 2012; 32(3): 733-8.
83. Yang YM, Chang JW. Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells. Cancer Invest 2008; 26(7): 725-33.
84. He X, Marchionni L, Hansel DE, et al. Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells 2009; 27(7): 1487-95.
85. Chan KS, Espinosa I, Chao M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 2009; 106(33): 14016-21.
86. Chan KS, Volkmer JP, Weissman I. Cancer stem cells in bladder cancer: a revisited and evolving concept. Curr Opin Urol 2010; 20(5): 393-7.
87. Peek EM, Li DR, Zhang H, et al. Stromal modulation of bladder cancer-initiating cells in a subcutaneous tumor model. Am J Cancer Res 2012; 2(6): 745-51.
88. Hepburn AC, Veeratterapillay R, Williamson SC, et al. Side Population in Human Non-Muscle Invasive Bladder Cancer Enriches for Cancer Stem Cells That Are Maintained by MAPK Signalling. PLoS One 2012; 7(11): e50690.
89. Zhang Q, Shi S, Yen Y, Brown J, Ta JQ, Le AD. A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett 2010; 289(2): 151-60.
90. Zhang P, Zhang Y, Mao L, Zhang Z, Chen W. Side population in oral squamous cell carcinoma possesses tumor stem cell phenotypes. Cancer Lett 2009; 277(2): 227-34.
91. Yao CJ, Lai GM, Yeh CT, et al. Honokiol Eliminates human oral cancer stem-like cells accompanied with suppression of Wnt/α-Catenin signaling and apoptosis induction. Evid Based Complement Alternat Med 2013; 2013: 146136.
92. Mýrgýritescu C, Pirici D, Simionescu C, Stepan A. The utility of CD44, CD117 and CD133 in identification of cancer stem cells (CSC) in oral squamous cell carcinomas (OSCC). Rom J Morphol Embryol 2011; 52(3 Suppl): 985-93.
93. Muramatsu T, Muramatsu H. Carbohydrate antigens expressed on stem cells and early embryonic cells. Glycoconj J 2004; 21(1-2): 41-5.
94. Noto Z, Yoshida T, Okabe M, et al. CD44 and SSEA-4 positive cells in an oral cancer cell line HSC-4 possess cancer stem-like cell characteristics. Oral Oncol 2013; 49(8): 787-95.
95. Su J, Xu XH, Huang Q, et al. Identification of cancer stem-like CD44+ cells in human nasopharyngeal carcinoma cell line. Arch Med Res 2011; 42(1): 15-21.
96. Janisiewicz AM, Shin JH, Murillo-Sauca O, et al. CD44(+) cells have cancer stem cell-like properties in nasopharyngeal carcinoma. Int Forum Allergy Rhinol 2012; 2(6): 465-70.
97. Wu A, Luo W, Zhang Q, et al. Aldehyde dehydrogenase 1, a functional marker for identifying cancer stem cells in human nasopharyngeal carcinoma. Cancer Lett 2013; 330(2): 181-9.
98. Yu F, Sim AC, Li C, et al. Identification of a subpopulation of nasopharyngeal carcinoma cells with cancer stem-like cell properties by high aldehyde dehydrogenase activity. Laryngoscope 2013; 123(8): 1903-11.
99. Luo WR, Gao F, Li SY, Yao KT. Tumour budding and the expression of cancer stem cell marker aldehyde dehydrogenase 1 in nasopharyngeal carcinoma. Histopathology 2012; 61(6): 1072-81.
100. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1(5): 555-67.
101. Boutonnat J, Barbier M, Muirhead K, et al. Response of chemosensitive and chemoresistant leukemic cell lines to drug therapy: simultaneous assessment of proliferation, apoptosis, and necrosis. Cytometry 2000; 42(1): 50-60.
102. Wang WJ, Wu SP, Liu JB, et al. MYC regulation of CHK1 and CHK2 promotes radioresistance in a stem cell-like population of nasopharyngeal carcinoma cells. Cancer Res 2013; 73(3): 1219-31.
103. Zhuang HW, Mo TT, Hou WJ, et al. Biological characteristics of CD133(+) cells in nasopharyngeal carcinoma. Oncol Rep 2013; 30(1): 57-63.
104. Lun SW, Cheung ST, Cheung PF, et al. CD44+ cancer stem-like cells in EBV-associated nasopharyngeal carcinoma. PLoS One 2012; 7(12): e52426.
105. Lin AM, Small EJ. Prostate cancer update: 2007. Curr Opin Oncol 2008; 20(3): 294-9.
106. Collins AT, Habib FK, Maitland NJ, Neal DE. Identification and isolation of human prostate epithelial stem cells based on alpha (2)beta(1)-integrin expression, J Cell Sci 2001; 114(pt 21): 3865-72.
107. Patrawala L, Calhoun T, Schneider-Broussard R, et al. Highly purified CD44t prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006; 25(12): 1696-708.
108. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumorinitiating cells. Cancer Res 2007; 67(14): 6796-805.
109. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004; 117(Pt 16): 3539-45.
110. Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998; 95(4): 1735-40.
111. Xin L, Lawson DA, Witte ON. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci USA 2005; 102(19): 6942-7.
112. Dall'Era MA, True LD, Siegel AF, Porter MP, Sherertz TM, Liu AY. Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urol 2007; 7: 3.
113. Havens AM, Jung Y, Sun YX, et al. The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis. BMC Cancer 2006; 6: 195.
114. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet 2003; 361(9354): 323-31.
115. Wang J, Sakariassen PØ, Tsinkalovsky O, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008; 122(4): 761-8.
116. Chen R, Nishimura MC, Bumbaca SM, et al. A hierarchy of selfrenewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010; 17(4): 362-75.
117. Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T, Matsutani M. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol 2006; 111(5): 483-8.
118. Christensen K, Aaberg-Jessen C, Andersen C, Goplen D, Bjerkvig R, Kristensen BW. Immunohistochemical expression of stem cell, endothelial cell, and chemosensitivity markers in primary glioma spheroids cultured in serum-containing and serum-free medium. Neurosurgery 2010; 66(5): 933-47.
119. Capela A, Temple S. LeX/ssea-1 is expressed by adult mouse CNS stem cells, identifying them as nonependymal. Neuron 2002; 35(5): 865-75.
120. Son MJ, Woolard K, Nam DH, Lee J, Fine HA. SSEA-1 is an enrichment marker for tumorinitiating cells in human glioblastoma. Cell Stem Cell 2009; 4(5): 440-52.
121. Balik V, Mirossay P, Bohus P, Sulla I, Mirossay L, Sarissky M. Flow cytometry analysis of neural differentiation markers expression in human glioblastomas may predict their response to chemotherapy. Cell Mol Neurobiol 2009; 29(6-7): 845-58.
122. Tchoghandjian A, Baeza N, Colin C, et al. A2B5 cells from human glioblastoma have cancer stem cell properties. Brain Pathol 2010; 20(1): 211-21.
123. Anido J, Sáez-Borderías A, Gonzàlez-Juncà A, et al. TGF-α Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. Cancer Cell 2010; 18(6): 655-68.
124. Biermann JS, Adkins D, Benjamin R, et al. Bone cancer. J Natl Compr Canc Netw 2007; 5(4): 420-37.
125. Lan J, Liu X, Rong W, et al. Stro-1(+) stromal cells have stem-like features in giant cell tumor of bone. J Surg Oncol 2012; 106(7): 826-36.
126. Adhikari AS, Agarwal N, Wood BM, et al. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res 2010; 70(11): 4602-12.
127. Veselska R, Hermanova M, Loja T, et al. Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines. BMC Cancer 2008; 8: 300.
128. Saini V, Hose CD, Monks A, et al. Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma. PLoS One 2012; 7(8): e41401.
129. Levings PP, McGarry SV, Currie TP, et al. Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res 2009; 69(14): 5648-55.
130. Aletti GD, Gallenberg MM, Cliby WA, Jatoi A, Hartmann LC. Current management strategies for ovarian cancer. Mayo Clin Proc 2007; 82(6): 751-70.
131. Baba T, Convery PA, Matsumura N, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133C ovarian cancer cells. Oncogene 2009; 28(2): 209-18.
132. Ferrandina G, Bonanno G, Pierelli L, et al. Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer 2008; 18(3): 506-14.
133. Alvero AB, Chen R, Fu HH, et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 2009; 8(1): 158-66.
134. Luo L, Zeng J, Liang B, et al. Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome. Exp Mol Pathol 2011; 91(2): 596-602.
135. Meirelles K, Benedict LA, Dombkowski D, et al. Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proc Natl Acad Sci USA 2012; 109(7): 2358-63.
136. Kang KS, Choi YP, Gao MQ, et al. CD24+ ovary cancer cells exhibit an invasive mesenchymal phenotype. Biochem Biophys Res Commun 2013; 432(2): 333-8.
137. Ziebarth AJ, Nowsheen S, Steg AD, et al. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clin Cancer Res 2013; 19(1): 170-82.
138. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67(3): 1030-7.
139. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1(4): 313-23.
140. Jaiswal KR, Xin HW, Anderson A, et al. Comparative testing of various pancreatic cancer stem cells results in a novel class of pancreatic-cancer-initiating cells. Stem Cell Res 2012; 9(3): 249-60.
141. Reid KM, Ramos-De la Medina A, Donohue JH. Diagnosis and surgical management of gallbladder cancer: a review. J Gastrointest Surg 2007; 11(5): 671-81.
142. Shi C, Tian R, Wang M, et al. CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Cancer Biol Ther 2010; 10(11): 1182-90.
143. Shi CJ, Gao J, Wang M, et al. CD133+ gallbladder carcinoma cells exhibit self-renewal ability and tumorigenicity. World J Gastroenterol 2011; 17(24): 2965-71.
144. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24(14): 2137-50.
145. Leelawat K, Thongtawee T, Narong S, Subwongcharoen S, Treepongkaruna SA. Strong expression of CD133 is associated with increased cholangiocarcinoma progression. World J Gastroenterol 2011; 17(9): 1192-8.
146. Agrawal S, Kuvshinoff BW, Khoury T, et al. CD24 expression is an independent prognostic marker in cholangiocarcinoma. J Gastrointest Surg 2007; 11(4): 445-51.
147. Keeratichamroen S, Leelawat K, Thongtawee T, et al. Expression of CD24 in cholangiocarcinoma cells is associated with disease progression and reduced patient survival. Int J Oncol 2011; 39(4): 873-81.
148. Wang M, Xiao J, Jiang J, Qin R. CD133 and ALDH may be the molecular markers of cholangiocarcinoma stem cells. Int J Cancer 2011; 128(8): 1996-7.
149. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11(1): 69-82.
150. Beck B, Driessens G, Goossens S, et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumors. Nature 2011; 478(7369): 399-403.
151. Platet N, Liu SY, Atifi ME, et al. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett 2007; 258(2): 286-90.
152. Iida H, Suzuki M, Goitsuka R, et al. Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2. Int J Oncol 2012; 40(1): 71-9.
153. Lauc G, Rudan I, Campbell H, et al. Complex genetic regulation of protein glycosylation. Mol Biosyst 2009; 6(2): 329-35.
154. Herscovics A. Importance of glycosidases in mammalian glycoprotein biosynthesis. Biochim Biophys Acta 1999; 1473(1): 96-107.
155. Mak AB, Blakely KM, Williams RA, et al. CD133 Nglycosylation processing contributes to cell-surface recognition of the primitive cell marker AC133. J Biol Chem 2011; 286(47): 41046-56.
156. Rangaswami H, Bulbule A, Kundu GC. Review Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006; 16(2): 79-87.
157. Stuelten CH, Mertins SD, Busch JI, et al. Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. Stem Cells 2010; 28(4): 649-60.
158. Bachmann MF, Speiser DE, Ohashi PS. Functional management of an antiviral cytotoxic T-cell response. J Virol 1997; 71(8): 5764-8.
159. Bernard A, Boumsell L. Human leukocyte differentiation antigens. Presse Med 1984; 13(38): 2311-6.
160. Fiebig H, Behn I, Gruhn R, Typlt H, Kupper H, Ambrosius H. Characterization of a series of monoclonal antibodies against human T cells. Allerg Immunol (Leipz) 1984; 30(4): 242-50. http://en. wikipedia. org/wiki/PubMedIdentifier.
161. Karbanova J, Missol-Kolka E, Fonseca AV, et al. The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia. J Histochem Cytochem 2008; 56(11): 977-93.
162. Jinesh GG, Choi W, Shah JB, Lee EK, Willis DL, Kamat AM. Blebbishields, the emergency program for cancer stem cells: sphere formation and tumorigenesis after apoptosis. Cell Death Differ 2013; 20(3): 382-95.